# Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1

> **NCT04393753** · PHASE2 · COMPLETED · sponsor: **4SC AG** · enrollment: 19 (actual)

## Conditions studied

- Merkel Cell Carcinoma

## Interventions

- **DRUG:** domatinostat in combination with avelumab

## Key facts

- **NCT ID:** NCT04393753
- **Lead sponsor:** 4SC AG
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-10-13
- **Primary completion:** 2024-02-26
- **Final completion:** 2024-02-26
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2024-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04393753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04393753, "Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT04393753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*